Title:

Impact of Standard versus Extended Natalizumab Dosing and Treatment Withdrawal on Relapse, Disability, MRI Activity and Safety in Adults with MS: A Systematic Review and Meta-Analysis

Authors:

- Vihaan Sahu
  ORCID: 0009-0008-5790-1818
  Georgian National University SEU, Tbilisi, Georgia

- Mohith Balakrishnan
  ORCID: 0009-0000-6053-7043
  Georgian National University SEU, Tbilisi, Georgia

- Dhaneesh Rucher Jetty
  ORCID: 0009-0005-7414-495X
  Georgian National University SEU, Tbilisi, Georgia

Corresponding Author:
Vihaan Sahu
Email: vsahu@seu.edu.ge

Acknowledgments:
Not applicable.

Abstract

Background: Natalizumab is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS). Balancing efficacy with the risk of progressive multifocal leukoencephalopathy (PML) is critical. Uncertainty persists regarding the comparative effectiveness of standard interval dosing (SID; every 4 weeks) versus extended interval dosing (EID; every 5-8 weeks) and the outcomes following treatment cessation.

Objectives: To systematically compare the efficacy and safety of natalizumab SID versus EID, and to quantify the absolute risk of relapse and disability progression after treatment cessation in adults with RRMS.

Methods: We conducted a systematic review and meta-analysis (PROSPERO: CRD420251103014) following PRISMA guidelines. We searched MEDLINE, Cochrane Library, ClinicalTrials.gov, and other sources (2015-2025) for randomized controlled trials and observational studies. Primary outcomes were annualized relapse rate (ARR) and disability progression; secondary outcomes included PML incidence and post-cessation relapse. Risk of bias was assessed using Cochrane RoB 2.0 and ROBINS-I. Data were synthesized narratively or via meta-analysis where appropriate, with evidence certainty graded (GRADE).

Results: Twenty-eight studies (3 RCTs, 24 observational studies, 1 case series; n=45,803 participants) were included. Narrative synthesis of ARR (9 studies) showed no consistent difference between SID and EID, with ARR values being very low in both groups. Meta-analysis of PML risk from three studies with events found no significant difference (RR 0.70, 95% CI 0.20–2.54). Disability outcomes were infrequently and heterogeneously reported, precluding meta-analysis. After cessation, the pooled proportion of patients relapsing within 12 months across 4 studies (n=857) was 37.6% (95% CI 34.4–40.9%). The certainty of evidence was low for most outcomes.

Conclusion: EID may maintain relapse control comparable to SID (low-certainty evidence). Long-term data suggest PML risk reduction with EID, but short-term evidence remains inconclusive. Cessation carries a high relapse risk (37.6% at 12 months), necessitating prompt therapy transition. Treatment decisions should be individualized. To definitively estimate PML risk, future research will require uniform outcome definitions and larger prospective trials.

Keywords: Natalizumab, multiple sclerosis, relapsing-remitting, extended interval dosage, treatment discontinuation, meta-analysis, progressive multifocal leukoencephalopathy.

# 1. Introduction

## 1.1 Background and Significance

MS is a chronic immune-mediated disease causing neurological disability. Globally affecting 2.8 million people, RRMS accounts for 85-90% of cases and typically presents in early adulthood (1-3). Effective disease-modifying therapy is crucial for managing relapses and disability progression. Hospitalization and large medical expenses are common among patients with severe RRMS, emphasizing the crucial need for effective disease-modifying therapy (4, 5).

Natalizumab, a humanized monoclonal antibody targeting α4-integrin, inhibits lymphocytes from crossing the blood-brain barrier, reducing CNS inflammation and relapse activity (6, 7). Since its FDA approval in 2004, natalizumab has demonstrated significant decreases in relapse frequency and MRI lesion burden in important trials (8, 3, 2). Following reports of progressive multifocal leukoencephalopathy (PML) in 2005, risk management strategies such as patient screening and JC virus surveillance were implemented (9, 10). Despite these developments, questions about optimal dosing regimens and safe withdrawal continue to arise. While standard four-week dose maintains α4-integrin receptor saturation above 80%, extended interval dosing (EID, 5-8 weeks) may reduce PML risk while maintaining efficacy (5). Discontinuation carries a 3-6-month risk of illness reactivation, emphasising the importance of evidence-based bridging treatments.

## 1.2 Current Evidence and Gaps

The phase 2 and pivotal studies consistently shown lower relapse rates and MRI lesion activity (8, 3, 2, 11). Early meta-analyses confirmed efficacy, but were restricted by short follow-up periods, dose variability, and a lack of long-term safety and post-cessation evidence. Nikfar et al. (12) (2010) analyzed four studies (n = 1,407) and discovered a 50% reduction in relapse risk, but the implications for real-world practice remained questionable. Observational studies, such as Salhofer-Polanyi et al. (13) (2014), indicate the danger of rebound following cessation, but variability in design and outcomes prevents definitive guidance. Recent systematic reviews, including Rabea et al. (14) (2024), explored safety and efficacy up to June 2023 but did not cover post-cessation outcomes or research beyond 2025, stressing the need for a modern synthesis that incorporates trial and observational data. A direct comparison table is provided in the below table A.

Table A.

| Aspect | Rabea et al. (2024) | Current Review |
|---|---|---|
| **Post-cessation data** | Not included | **Comprehensive synthesis** (n = 857; 37.6% relapse at 12 mo) |
| **Latest studies** | Up to June 2023 | **Up to 2025** (8 new studies) |
| **PML duration analysis** | Not stratified | **Stratified by treatment duration** |
| **Real-world focus** | Limited | **45,803 patients** (registries + RCTs) |

1.3 Rationale for this Review

While the efficacy of natalizumab has been demonstrated, information on EID and post-discontinuation outcomes remains fragmented. Real-world accounts emphasize rebound risk and the significance of bridging techniques, but heterogeneity limits conclusive guidance. This review builds on previous work by including studies from 2023-2025, combining trial and real-world data, and focusing on dose optimization and cessation to inform interval management techniques.

1.4 Objectives

This systematic review and meta-analysis aims to evaluate Natalizumab in adults with RRMS, with an emphasis on dosing strategies and outcomes after cessation. Using a PICO framework, the objectives are:

- To compare the efficacy of standard-interval dosing (SID) versus extended-interval dosing (EID) on annualized relapse rate (ARR), disability progression, and MRI outcomes.
- To quantify the absolute risk, timing, and severity of relapse and disability progression following treatment cessation.
- To evaluate safety profiles, particularly the incidence of PML.
- To synthesize real-world and trial evidence from 2015 onward.
- To support clinical decision-making by offering evidence on dose optimization and cessation procedures.

2. Methods

2.1 Protocol and Registration

This systematic review was conducted according to a predefined protocol registered on PROSPERO (CRD420251103014). The protocol specified the search strategy, eligibility criteria, outcomes, risk-of-bias assessment methods, and synthesis approach. The review is reported in accordance with the PRISMA 2020 statement (15).

2.2 Eligibility Criteria

Studies were selected based on the PICO framework:

- Population: Adults (≥18 years) with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab monotherapy.
- Intervention: 1) Standard-interval dosing (SID) of natalizumab (every 4 weeks), or 2) Cessation of natalizumab therapy.
- Comparator: 1) Extended-interval dosing (EID; infusion intervals typically >4 weeks, up to 8 weeks), or 2) For cessation studies, either continuation of natalizumab or no active comparator (natural history).

- Outcomes:The primary outcomes were the annualized relapse rate (ARR) and disability progression (confirmed EDSS deterioration). Secondary outcomes included No Evidence of Disease Activity (NEDA-3), relapse risk after cessation, MRI activity, and safety outcomes, specifically the incidence of progressive multifocal leukoencephalopathy (PML).
- Study Designs: Randomized controlled trials (RCTs), prospective and retrospective cohort studies, and case series (for cessation results) were all included. Studies were omitted if they were reviews, conference abstracts without full data, addressed pediatric populations, coupled natalizumab with other disease-modifying treatments, or did not provide relevant outcomes. To reflect current practice, the publishing date range began on January 1, 2015. While the protocol specified studies from 2015 onward, one study (16)) was first published online in November 2014 but assigned to a 2015 journal issue; given its direct relevance, it was retained. This represents a minor deviation from the protocol. Only English-language publications were included.

## 2.3 Information Sources

We searched MEDLINE, Cochrane Library, and ClinicalTrials.gov from 2015-2025, with additional studies identified through reference screening and author contact.

## 2.4 Search Strategy

Search strategies combined MeSH terms and keywords for natalizumab, MS, dosing strategies, cessation, relapse, disability, and PML. Filters: human studies, English, 2015-2025. The search strategy was tailored for each database and is available on PROSPERO protocol registration.

## 2.5 Study Selection

Search results were imported into Zotero 6.0.30 for duplicate removal. Title/abstract screening and subsequent full-text assessment were performed independently by two reviewers (V.S., M.B.) using Rayyan QCRI (17) . Conflicts were resolved through discussion or by a third reviewer (D.J.). The study selection process is detailed in the PRISMA flow diagram (18) (Figure 1).

Figure 1: PRISMA flow chart

## 2.6 Data Collection Process

Data extraction was conducted independently by two reviewers (V.S., D.J.) using a standardized, piloted data extraction form in LibreOffice and Word. Disagreements were resolved by consensus or third-party adjudication (M.B.). Study authors were contacted for clarification or additional data when reported information was incomplete.

## 2.7 Data Items

Extracted data included:

- Study characteristics (design, country, funding, conflicts of interest).
- Participant characteristics (sample size, demographics, baseline disease characteristics).
- Intervention and comparator definitions (specific EID interval, cessation reason, post-cessation management).
- Outcome data for all pre-specified efficacy and safety endpoints, including effect estimates, measures of dispersion, and raw counts/denominators where available.

2.8 Risk of Bias in Individual Studies

The risk of bias was assessed independently by two reviewers (V.S., M.B.).

- RCTs (n = 3) were evaluated using the Cochrane RoB 2.0 tool (19).
- Non-randomized studies (n = 24) were assessed using the ROBINS-I tool (20).
- Case series (n = 1) were appraised using the Joanna Briggs Institute (JBI) critical appraisal checklist (21).

Results are summarized graphically in Supplementary Figure 1A (RCTs) and Supplementary Figure 1B (non-randomized studies), which were generated using the robvis visualization tool (22). Detailed domain-level judgments for all studies are provided in Supplementary Table 1.

2.9 Synthesis Methods

- Synthesis approach depended on clinical and methodological homogeneity. Meta-analysis used random-effects models for consistent outcomes. For rare events (PML), only studies reporting events were pooled. Person-year data were analyzed separately. Heterogeneity was quantified using $I^2$.

- Narrative synthesis followed SWiM guidelines for outcomes with extreme heterogeneity. For ARR, meta-analysis was precluded due to EID definition variability (5-8 weeks), inconsistent reporting (7 calculation methods), and missing data. Median ARR difference was 0.00 (range -0.05 to +0.01).

Sensitivity analyses assessed robustness. Evidence certainty was evaluated using GRADE (24) (Supplementary Table 4).

2.10 Software

We used Zotero, Rayyan QCRI (17) , R statistical software (25) with the meta package (26), and LibreOffice/Word for data management and analysis.

3. Results

3.1 Study Selection

Our systematic search identified 1,338 records (1,316 from databases and 22 from trial registries), with an additional 12 records found through citation searching. After removing 297 duplicates, 1,041 titles and abstracts were screened, of which 818 were excluded for irrelevance.
We assessed 223 full texts from databases/registries and 12 from citation searches. Nine full texts (7 database/register, 2 citation) could not be retrieved. Of the remaining 225 reports, 199 (189 database/register and 10 citation) were excluded due to ineligible study design, population, intervention, or outcomes.

Ultimately, 28 studies met inclusion criteria (27 from databases/registries, 1 from citation searching). The PRISMA 2020 flow diagram (18) (Figure 1) summarizes the selection process, and excluded studies are listed in Supplementary Table 2.

3.2 Study Characteristics

The 28 included studies (2015–2025) comprised 3 randomized controlled trials (RCTs), 24 observational studies (prospective and retrospective cohorts), and 1 case series. Across all studies, the total sample size was 45,803 participants, although one large registry (Ryerson et al. (27), n=35,521) heavily influenced this number. Studies were conducted in single-country or multinational settings across Europe, North America, the Middle East, and Australia.

Two primary comparisons were addressed:

- Standard-Interval Dosing (SID) vs Extended-Interval Dosing (EID) of natalizumab, with EID definitions ranging from >5 weeks to 8-week intervals.
- Outcomes after cessation of natalizumab.

The key reported outcomes were annualized relapse rate (ARR), disability progression (EDSS worsening), NEDA-3, PML incidence, and post-cessation outcomes (relapse rates, time to relapse, and EDSS worsening). Funding was disclosed for 22 trials, with 10 getting industrial support, largely from Biogen. Table 1 summarizes the detailed study characteristics, including the baseline demographics.

TABLE 1. Characteristics of Included Studies

| Study (Author, Year) | Country | Study Design | Sample Size (Total N) | Comparison Groups | Funding Source / Conflict of Interest | Notes |
|---|---|---|---|---|---|---|
| Al-Mahdawi et al., 2023 (28) | Iraq | Observational Retrospective Cohort | 150 | SID (Q4W), EID (definition NR) | NR | Multicenter, aggregated data only (contributed to narrative context) |
| Bernardes et al., 2024 (29) | Portugal | Retrospective observational cohort | 76 | SID (Q4W) vs EID (Q6W) | No specific grant; COI disclosed | Single-center, within-patient comparison |
| Butzkueven et al., 2020 (TOP) | Multinational | Prospective Observatio | 472 (matche | SID (Q4W), EID (Q6W) | Supported by Biogen; multiple author COIs | Multicenter registry, |

| | | | | | | |
|---|---|---|---|---|---|---|
| (30) | nal Registry | d) | | | | propensity score-matched |
| Clerico et al., 2019 (31) | Italy | Retrospective Cohort | 360 | SID (<5 weeks), EID (≥5 weeks) | NR | Multicenter (14 centers) |
| Coerver et al., 2021 (32) | Netherlands | Retrospective Observational Cohort | 147 | Cessation | ZonMW grant, Stichting MS Research grant | Monocentric, outcomes after cessation |
| De Mercanti et al., 2021 (33) | Italy | Retrospective cohort | 316 | SID (<5w) vs EID (≥5w) | Not reported | Multicenter (14 centers) |
| Foley et al., 2022 (NOVA) (34) | Multinational (11 countries) | RCT (open-label, rater-blinded) | 499 | SID (Q4W) vs EID (Q6W) | Biogen | Multicenter (89 centers), phase 3b trial |
| Fuentes-Rumí et al., 2020 (35) | Spain | Retrospective observational | 50 | Cessation | No specific grant; COI disclosed | Single-center, IVMP washout strategies |
| Gardinetti et al., 2017 (36) | Italy | Retrospective Cohort | 30 | Cessation | All authors have nothing to declare | Multicenter (2 centers), outcomes after cessation |
| González-Suarez et al., 2017 (37) | Spain | Case series | 4 | Cessation → switch to FTY | "No conflict of interest" | Multicenter (3 hospitals), rebound cases |
| Haas et al., 2016 (38) | Germany | Prospective cohort | 57 | SID (Q4W) vs Cessation (Wash-out) | German Ministry for Education and Research; "none | Single-center, immunology focus |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | declared" | | |
| Jakimovski et al., 2023 (39) | USA (NY) | Retrospective cohort | 242 | Continue SID (Q4W) vs Discontinue (Cessation) | Biogen; Multiple authors disclosed industry funding | Consortium data, includes SPMS/PPMS patients |
| Jeantin et al., 2023 (40) | France | Retrospective Self-Controlled Cohort | 57 | SID (Q4W), EID (Q6W) | No funding; some author COIs | Monocentric, within-patient comparison |
| Kaufman et al., 2015 (RESTORE) (41) | Multinational | RCT | 175 | Continue Natalizumab (Q4W), Placebo (Cessation) | Funded by Biogen Idec Inc. | Multicenter, partially placebo-controlled |
| Kister et al., 2018 (42) | Multinational (20 centers) | Retrospective registry cohort | 4842 | Cessation (vs other DMTs) | MSBase Foundation; "No targeted funding" | MSBase registry, natalizumab cessation arm n=308 |
| Mustonen et al., 2020 (43) | Finland | Retrospective cohort | 89 (85 RRMS) | Cessation | Hospital grants; personal grants; honoraria/consultancies | Multicenter (4 hospitals), RRMS n=85 for PICO |
| Papeix et al., 2016 (44) | France | Prospective observational registry | 715 | Cessation | No targeted funding; COI disclosed | Nationwide multicenter (TYSEDMUS registry) |
| Pelle et al., 2023 (45) | France | Retrospective cohort | 303 | SID (Q4W) vs EID (5-6w) | Caen University Hospital; additional funding from Biogen | Multicenter (5 centers) |

| Study | Country | Design | N | Dosing | Funding | Setting |
|---|---|---|---|---|---|---|
| Riancho et al., 2021 (46) | Spain | Retrospective Cohort | 39 | SID (Q4W), EID (Q8W) | Supported by IDIVAL; various author COIs | Monocentric, within-patient comparison (sequential arms) |
| Ruggieri et al., 2019 (47) | Italy | Retrospective Cohort | 775 | SID (≤35 days), EID (>35 and ≤56 days) | NR | Multicenter, includes a mixed-dose arm |
| Ryerson et al., 2015 (48) | USA | Registry Analysis | 1998 | SID (Q4W ±2d), EID (4w3d-8w5d) | No grant or industry support | Multicenter registry |
| Ryerson et al., 2019 (27) | USA | Retrospective Cohort (TOUCH) | 35,521 | SID (various def.), EID (various def.) | Funded by Biogen | TOUCH registry, analysis of PML risk only |
| Ruggieri et al., 2024 (49) | Italy | Retrospective Cohort | 745 | SID (Q4W), EID (>5-7 weeks), EID (>7-8 weeks) | Multiple author COIs with pharma companies | Multicenter (8 centers), arm Ns not reported |
| Toorop et al., 2024 (50) | Netherlands | Retrospective Cohort | 82 | SID (Q4W), EID (≥5 weeks) | Dutch MS Research Foundation, Brain Foundation Netherlands, Innovation Fund Healthcare insurers | Monocentric |
| van Kempen et al., 2020 (51) | Netherlands | Prospective single-arm trial | 61 | EID (Personalized) | Brain Foundation Netherlands; Various COI disclosures | Multicenter, no SID comparator arm |
| Vidal-Jordana | Spain | Prospective | 47 | Cessation | No specific grant | Single-center, |

| | | | | | |
|---|---|---|---|---|---|
| et al., 2015 (16) | | observation al cohort | | | outcomes after cessation |
| Weinstock-Guttman et al., 2016 (52) | USA | RCT (single-blinded MRI) | 50 | Cessation: Tapered (EID-like) vs Immediate | Biogen Idec (Investigator-initiated) | Single-center, phase IV, includes relapsing-SPMS |
| Yamout et al., 2018 (53) | Lebanon, Iran | Retrospecti ve Review of Registry Cohorts | 85 | SID (Q4W), EID (≥5 weeks) | None | Multicenter (2 centers), within-patient comparison |

*Footnote: SID = standard-interval dosing; EID = extended-interval dosing; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; PPMS = primary progressive multiple sclerosis; NR = not reported.*

## 3.3 Risk of Bias

RCTs (n=3) were evaluated using ROB 2 (19): two were judged low risk, while one raised some concerns due to deviations from intended interventions.
Non-randomized studies (n=24) were assessed with ROBINS-I (20): 20 had moderate risk and 4 serious risk.

Confounding and missing data were the most common sources of bias. A case series (37) assessed with the JBI checklist was deemed moderate risk. Full risk-of-bias judgments are provided in Supplementary Table 1 and Supplementary Figures 1A and 1B.

## 3.4 Synthesis of Results

Feasibility of quantitative meta-analysis was pre-assessed for each outcome based on clinical and methodological homogeneity (Supplementary Table 3).

### 3.4.1 SID vs EID: Efficacy Outcomes (ARR)

Thirteen studies reported ARR, of which 9 provided data suitable for descriptive synthesis. ARR values were consistently low across both dosing strategies (range: 0.0006–0.14).

Based on the direction of point estimates, four studies reported a lower ARR with EID, three reported a lower ARR with SID, and two reported identical or nearly identical ARR between groups.

- The median ARR difference (EID – SID) was 0.000 (range –0.050 to +0.014).

- Pelle 2023 (45) was the only study allowing formal IRR estimation (IRR 0.44; 95% CI 0.16–1.26), showing no significant difference.

Table 3A summarizes ARR outcomes. Meta-analysis was not possible due to heterogeneity in EID definitions, outcome reporting, and lack of raw event data.

Summary: Both SID and EID maintained very low relapse activity. No strategy consistently outperformed the other.

Table 3A: ARR Comparison: Study Characteristics and Reported Outcomes

| Study | EID Definition | Reported ARR (Quote/Direct Summary) | Notes |
|---|---|---|---|
| Bernardes 2024 (29) | 6 weeks | ARR, median (IQR) 0 (0) [SID] vs 0 (0) [EID]; Relapses: 1 [SID] vs 4 [EID], p=0.083 | Within-patient comparison; PY not reported |
| Clerico 2019 (31) | ≥5 weeks | Adjusted ARR: 0.060 (95% CI 0.033–0.087) [SID] vs 0.039 (95% CI 0.017–0.063) [EID] | Adjusted mean; no raw counts/PY |
| De Mercanti 2021 (33) | ≥5 weeks | ARR 0.075 (SD 0.20) [SID] vs 0.089 (SD 0.22) [EID] | Pre-intervention period |
| Foley 2022 (34) | 6 weeks | Unadjusted ARR 0.0171 [SID] vs 0.0228 [EID]; Adjusted ARR: 0.00010 (95% CI 0.00004–0.00024) [SID] vs 0.00013 (95% CI 0.00006–0.00027) [EID] | Relapse counts not reported |
| Jeantin 2023 (40) | 6 weeks (42 ± 7 days) | ARR 0.0 [SID] vs 0.0 [EID] | Zero relapses; PY calculable |
| Pelle 2023 (45) | 5–6 weeks (≤9 | ARR 0.083 (SD 0.300) [SID] | Only study with |

| | | vs 0.041 (SD 0.231) [EID]; Relapses: 12/156 [SID] vs 5/147 [EID] | counts & PY suitable for IRR |
|---|---|---|---|
| Riancho 2021 (46) | 8 weeks | ARR 0.025 (SD 0.026) [SID] vs 0.020 (SD 0.060) [EID]; p=0.72 | Mean ARR only |
| Ryerson 2015 (48) | 4.5–8.5 weeks | ARR 0.14 [SID] vs 0.09 [EID] | Mean ARR only |
| Yamout 2018 (53) | ≥5 weeks | ARR 0.0006 ± 0.003 [SID] vs 0.001 ± 0.006 [EID]; p=0.42 | Mean ARR and SD |

*Footnotes: SID = standard-interval dosing; EID = extended-interval dosing; ARR = annualized relapse rate; SD = standard deviation; PY = person-years; CI = confidence interval.*

Figure 2. Annualized Relapse Rate (ARR) Values by Study (Narrative Synthesis).

**ARR Values by Study (Narrative Synthesis)**

Figure 3. Annualized Relapse Rate (ARR) Comparison: SID vs EID across the included studies.

3.4.2 SID vs EID: Disability Progression and NEDA-3

Heterogeneous outcome definitions and insufficient reporting prevented quantitative synthesis.

- Foley 2022 (34): 24 weeks of reported disability worsening: 92% [SID] vs 90% [EID] progression-free;
- NEDA-3: 163/242 [SID] vs 173/247 [EID].
- Pelle 2023 (45): Unconfirmed EDSS worsening: 13% [SID] versus 11% [EID].
- Riancho 2021 (46): Partial NEDA-3 reporting for EID only.

Table 3B presents study-specific outcomes.

Summary: Disability progression and NEDA-3 failure rates were modest across all regimens. The evidence shows equivalency, although comparability was constrained by inconsistent outcome criteria.

Table 3B: Disability Progression and NEDA-3 Outcomes

| Outcome | PICO Comparison | Study | Outcome Definition | Reported Results | Notes |
|---|---|---|---|---|---|
| EDSS Worsening | SID vs EID | Foley 2022 (34) | 24-week confirmed disability worsening | % free of progression: 92% [SID] vs 90% [EID] | Raw event counts not reported. |
| | SID vs EID | Pelle 2023 (45) | Worsening of EDSS score (not confirmed) | 20 (13%) [SID] vs 14 (11%) [EID] | Definition is not confirmed disability progression. |
| | After Cessation | Vidal-Jordana 2015 (16) | Increase of ≥1.5 or ≥1.0 point at 6-12mo | Eight patients (19%) presented significant clinical worsening | Single arm reporting only. |
| NEDA-3 | SID vs EID | Foley 2022 (34) | No relapses, no new MRI lesions, no 24-wk | NEDA-3: 163/242 [SID] vs 173/247 [EID] | Only study reporting complete NEDA-3 data. |

| | | CDW | | |
|---|---|---|---|---|
| SID vs EID | Riancho et al., 2021 (46) | Not fully defined | Proportions for EID arm only (94%, 73%, 70%) | Incomplete reporting; no SID data. |

*Footnote: EDSS = Expanded Disability Status Scale; CDW = Confirmed Disability Worsening; NEDA-3 = No Evidence of Disease Activity (relapses, MRI activity, and CDW)*

### 3.4.3 SID vs EID: Safety Outcome (PML)

Nine studies reported on PML. Given PML typically requires >24 months of natalizumab exposure, we conducted a duration-stratified analysis. The meta-analysis of risk ratio (RR) included three studies reporting PML events, with five additional studies reporting zero events in both arms presented in Table 3C for context (not included in pooled RR calculation).

- **Long-term exposure (>24 months)**: Ryerson et al. 2019 (27) (n=35,521) demonstrated a 94% PML risk reduction with EID (adjusted HR 0.06, 95% CI 0.01–0.44) in JCV-positive patients. Ryerson et al. 2015 (48) person-year analysis (IRR 0.11, 95% CI 0.01–1.99) supported this trend in JCV-positive patients.

- **Short-term exposure (<24 months)**: Butzkueven et al. 2020 (30) (median ~2 years) reported two PML cases in each group (SID n=210, EID n=236). Foley et al. 2022 (34) (72 weeks) reported one asymptomatic PML case in EID (n=247) and none in SID (n=242).

Primary pooled analysis (3 studies with events): RR 0.70 (95% CI 0.20–2.54), I²=0%. Sensitivity analysis (excluding Foley 2022 asymptomatic case): RR 0.54 (95% CI 0.13–2.17). The pooled estimate was attenuated by inclusion of short-term studies with limited events and variable follow-up. Table 3C summarizes study-level PML data with exposure duration.

**Summary**: While the pooled analysis showed no significant difference in PML risk (RR 0.70), long-term data from Ryerson et al. (27) demonstrated substantial PML risk reduction with EID (94%) in patients with prolonged exposure. This discrepancy highlights limitations in meta-analyzing rare events without accounting for treatment duration. Ongoing monitoring remains warranted, particularly for long-term users.

**Table 3C:** PML Incidence in Patients on Standard-Interval Dosing (SID) vs. Extended-Interval Dosing (EID)

| STUDY (FIRST AUTHOR, YEAR) | DOSING GROUP | POPULATION AT RISK | PML EVENTS (N) | EXPOSURE DURATION | KEY NOTES |
|---|---|---|---|---|---|
| Studies Included in RR Meta-analysis | | | | | |
| Butzkueven et al., 2020 (30) | SID | 210 (N) | 2 | Median ~2 years | Safety population |

| STUDY (FIRST AUTHOR, YEAR) | DOSING GROUP | POPULATION AT RISK | PML EVENTS (N) | EXPOSURE DURATION | KEY NOTES |
|---|---|---|---|---|---|
| Ryerson et al., 2019 (27) | EID | 236 (N) | 2 | Median ~2 years | Safety population |
| | SID | 4801 (N)* | 19 | >24 months | Adjusted JCV+ patients |
| | EID | 810 (N) | 1 | >24 months | Adjusted JCV+ patients |
| Foley et al., 2022 (34) | SID | 242 (N) | 0 | 72 weeks (~1.4 years) | Clinical & MRI monitoring |
| | EID | 247 (N) | 1 (asymptomatic) | 72 weeks (~1.4 years) | Asymptomatic case via MRI |
| Study with Person-Year Data | | | | | |
| Ryerson et al., 2015 (48) | SID | 1052 PY** | 4 | JCV+ PY | JCV+ person-years |
| | EID | 1090 PY** | 0 | JCV+ PY | JCV+ person-years |
| Studies with Zero PML Events | | | | | |
| Clerico et al., 2019 (31) | SID | 216 (N) | 0 | Up to 2 years | Follow-up up to 2 years |
| | EID | 144 (N) | 0 | Up to 2 years | Follow-up up to 2 years |
| Pelle et al., 2023 (45) | SID | 156 (N) | 0 | 12 months | 12 months follow-up |
| | EID | 147 (N) | 0 | 12 months | 12 months follow-up |
| Riancho et al., 2021 (46) | SID | 39 (N) | 0 | Mean 51.1 months | Mean follow-up |
| | EID | 39 (N) | 0 | Mean 76.7 months | Mean follow-up |
| Toorop et al., 2024 (50) | SID | 50 (N) | 0 | Not specified | Follow-up not specified |
| | EID | 32 (N) | 0 | Not specified | Follow-up not specified |
| Yamout et al., 2018 (53) | SID | 85 (N) | 0 | Not specified | Follow-up not specified |
| | EID | 85 (N) | 0 | Not specified | Follow-up not specified |

Footnote: EID: Extended-Interval Dosing; JCV: JC virus; MRI: Magnetic Resonance Imaging; N: Number of patients; PML: Progressive Multifocal Leukoencephalopathy; PY: Person-Years; SID: Standard-Interval Dosing

Figure 4: Forest Plot of PML Risk: SID vs EID (Main Analysis).

Heterogeneity: $\chi^2_2 = 1.45$ ($P = .48$), $I^2 = 0.0\%$
Test for overall effect: $z = -0.54$ ($P = .59$)

Supplementary Figure 2: Forest Plot of PML Risk is also provided which includes Sensitivity Analysis Excluding Foley et al. 2022 (34).

3.4.4 Outcomes After Cessation: Relapse and Disability

Four studies (n=857) reported the proportion of patients relapsing within 12 months post-cessation. This was meta-analyzed as a pooled proportion (absolute risk).

- Pooled proportion of patients relapsing: 37.6% (95% CI 34.4–40.9%).
- Heterogeneity: $I^2$=66.1%, largely due to Weinstock-Guttman 2016 (52) (59.3%). Excluding this outlier reduced $I^2$ to 0%, with minimal change in pooled estimate (35.2%).

EDSS worsening rates post-cessation were highly variable (19–100%). Excluding the outlier study (González-Suarez et al., 2017 (37), n=4), the weighted mean was 23.1%. Median time to first relapse ranged from 3-9.8 months, clustering within the first 6 months.

Table 3D summarizes cessation outcomes.

Summary: Natalizumab cessation was associated with a high absolute risk of relapse (≥1/3 relapsing within 12 months) and frequent EDSS worsening, with most relapses occurring early.

Table 3D: Outcomes After Natalizumab Cessation

| Study | N (Stop) | Primary Reason for Cessation | Follow-up post-cessation | % Relapse (12mo) | Median Time to First Relapse (months) | % with EDSS Worsening | Post-Cessation Strategy |
|---|---|---|---|---|---|---|---|
| Coerver et al., 2021 (32) | 147 | JCV positivity/PM | 2 years | NR | 6.1–9.8 (by | 18.0–22.7% | No DMT, First-line, or |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | L risk (64.6%) | | | group) | | Second-line DMT |
| Gardinetti et al., 2017 (36) | 30 | Planned interruption | Mean 18.8 mo | 50% | 6.0 (mean) | NR | Various (not specified) |
| Mustonen et al., 2020 (43) | 85 | Various | ≥12 months | 30.3% | 3.0 (rebound subgroup) | NR | Switch to another DMT |
| Papeix et al., 2016 (44) | 715 | Various | Median 1.1 yr | 37.1% | 4.9 | 23% | Restart NTZ or switch to another DMT |
| Weinstock-Guttman et al., 2016 (52) | 27 | Study protocol | 12 months | 59.3% | NR | NR | Switch to another DMT |
| *Additional descriptive studies* | | | | | | | |
| González-Suarez et al., 2017 (37) | 4 | PML risk | NR | NR | 3.5 (mean) | 100% | Switch to fingolimod |
| Vidal-Jordana et al., 2015 (16) | 47 | PML risk, other | Mean 23.9 mo | NR | NR | 19% | Switch to another DMT |

*Footnote: NR = Not Reported; DMT = disease-modifying therapy; NTZ = natalizumab.*

Figure 5. Forest plot of the proportion of patients relapsing within 12 months after natalizumab cessation (random-effects model).

Figure 6. Timeline of median/mean time to first relapse across studies reporting this outcome.

Figure 7. Bar plot of EDSS worsening rates after cessation. The weighted mean excluding the outlier (37) was 23.1%.

**EDSS Worsening After Natalizumab Cessation**

## 3.5 Sensitivity Analyses

Leave-one-out analyses confirmed robustness of pooled results for both PML risk and cessation relapse rates. Exclusion of single studies influenced heterogeneity but not overall interpretation (Supplementary Table 5).

## 3.6 Reporting Bias

Publication bias could not be formally assessed as each outcome had fewer than 10 studies, insufficient for funnel plots or statistical testing.

## 3.7 Certainty of Evidence (GRADE)

Certainty of evidence for each outcome is summarized in Supplementary Table 4:

- SID vs EID:
- o ARR = Low (risk of bias, inconsistency)
- o Disability progression = Very Low (bias, inconsistency, indirectness)
- o PML = Low (bias, imprecision)
- o NEDA-3 = Low (bias, imprecision, single study)

- Outcomes After Cessation:
- o Relapse = Low (bias, heterogeneity)

- EDSS worsening = Very Low (bias, inconsistency, imprecision)

*The evidence for PML risk reduction was upgraded from Very Low to Low for long-term users (>24mo) based on the large effect size (94% reduction) in Ryerson 2019.*

4. Discussion.

4.1. Interpreting the Results

This systematic review presents a complete synthesis of evidence comparing standard-interval dosing (SID) with extended-interval dosing (EID) of natalizumab in RRMS, including outcomes after treatment discontinuation. Our analysis includes 28 trials totaling 45,803 participants. The evidence showed significant clinical and methodological variation, which influenced our analytical approach.

The efficacy outcomes for SID vs. EID were similar in direction but varied in reporting. Across nine trials reporting ARR, the median difference (EID - SID) was zero. The point estimates fluctuated, with no clear trend favoring one technique over another. These findings indicate that EID provides relapse control comparable to SID. Similarly, when disability progression and NEDA-3 results were reported, they were modest and similar between groups, despite the limitations of different classifications.

The safety outcomes, specifically PML incidence, were meta-analyzed across the three studies that recorded occurrences. The pooled risk ratio was 0.70 (95% confidence interval: 0.20–2.54). While our point estimate shows that EID may reduce PML risk, the confidence intervals are broad and can account for both clinically significant benefit and harm. The frequency of PML episodes, combined with the observational nature of the evidence, limits the certainty of this discovery. Our pooled PML estimate (RR 0.70) conflicts with Ryerson 2019's 94% reduction because meta-analysis of rare events is highly sensitive to study duration. When restricted to long-term users (>24mo), EID shows significant PML risk reduction, supporting its use in JCV+ patients with prolonged exposure.

The outcomes upon cessation were evident. The pooled proportion of patients relapsing within 12 months was 37.6%, indicating a substantial absolute risk of illness reactivation following natalizumab withdrawal and emphasizing the importance of proactive transition programs.

4.2. Limitations of the Evidence

Key limitations include predominance of observational studies, heterogeneity precluding meta-analysis for some outcomes, and imprecise PML estimates due to rare events. Residual confounding cannot be excluded.

4.3. Limitations of the Review Procedure

Our review followed PRISMA 2020 guidelines (15). However, several limitations should be acknowledged. The search was restricted to studies published after 2015 and in English, which may have induced bias. Due to heterogeneity in outcome definitions, narrative synthesis was required for the majority of efficacy outcomes.

Finally, the small number of papers for each outcome limited our formal assessment of publication bias. The inclusion of one study from late 2014 (published in 2015) is a minor change from the protocol, stated for transparency.

4.4 Implications for Practice and Research

Clinical implications: For patients with stable RRMS, EID (≤8 weeks) may provide a reasonable balance of efficacy and convenience. However, the choice to lengthen dose intervals should be made on an individual basis. PML risk should not be the primary reason for switching to EID, as the evidence is still equivocal. Our findings highlight the importance of starting alternative therapy as soon as possible for patients who have stopped using natalizumab.

Future research should focus established criteria for EID and outcomes, large prospective registries with adjusted confounders, RCTs powered by clinical outcomes, and comparative efficacy research on post-cessation interventions.

5. Conclusion.

This systematic review compiles data from 28 studies on natalizumab dosing and discontinuation in relapsing-remitting multiple sclerosis. It suggests that extended-interval dosing (EID; up to 8 weeks) *may* maintain relapse control comparable to standard-interval dosing (SID) (low certainty evidence). For PML risk reduction, long-term registry data (Ryerson 2019) suggest potential benefit with EID in patients with prolonged exposure, but short-term evidence remains inconclusive. The discontinuation of natalizumab is associated with a significant absolute risk of disease reactivation, with a pooled 37.6% of patients relapsing within 12 months (low certainty evidence).

In clinical practice, these findings indicate that EID *might* be considered for stable patients, primarily for convenience reasons, but should not be adopted solely for PML risk reduction given current evidence limitations. The high relapse risk following cessation underscores the critical need for prompt initiation of alternative therapy. Treatment decisions should be **individualized**, considering patient-specific factors and preferences, and based on ongoing risk-benefit assessment. Future research should focus on prospective studies with consistent outcome definitions, larger sample sizes, and longer follow-up to definitively establish the risk-benefit profile of EID, particularly regarding PML risk reduction.

6. Statements and Declarations
6.1 Competing Interests
The authors declare that they have no competing interests.

6.2 Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

6.3 Ethics Approval and Consent to Participate
Not applicable. This study is a systematic review and meta-analysis of previously published data.

6.4 Consent for Publication
Not applicable.

6.5 Availability of Data and Materials
All data analyzed in this study were obtained from previously published sources. No new datasets were generated or analyzed during the current study.

6.6 Author Contributions
All authors contributed to the conception, study design, data extraction, analysis, interpretation, and drafting of the manuscript. All authors read and approved the final version of the manuscript.

7. References

1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816–21.

2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910.

3. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 Jan 2;348(1):15–23.

4. Ohlmeier C, Gothe H, Haas J, Osowski U, Weinhold C, Blauwitz S, et al. Epidemiology, characteristics and treatment of patients with relapsing-remitting multiple sclerosis and incidence of high disease activity: real-world evidence based on German claims data. PLoS One. 2020;15(5):e0231846.

5. Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord. 2014 Sep;7(5):227–31.

6. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2008;5(1):16–22.

7. McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013 Sep;73(13):1463–81.

8. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology. 1999 Aug 10;53(3):466–72.

9. Sheridan C. Tysabri back on market. Nat Biotechnol. 2006 Aug;24(8):874.

10. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar

2;354(9):924–33.

11. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911–23.

12. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci. 2010 Apr 30;6(2):236–44.

13. Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand. 2014 Aug;130(2):97–102.

14. Rabea EM, Belal MM, Hafez AH, Elbanna AH, Khalifa MA, Nourelden AZ, et al. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Acta Neurol Belg. 2024 Apr;124(2):407–17.

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.

16. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Mult Scler. 2015 May;21(6):780–5.

17. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016 Dec 5;5(1):210.

18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.

19. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898.

20. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919.

21. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020 Oct;18(10):2127–33.

22. McGuinness LA, Higgins JPT. Risk-of-bias Visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021 Jan;12(1):55–61.

23. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020 Jan 16;368:l6890.

24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924–6.

25. R Core Team. R: The R Project for Statistical Computing [Internet]. Vienna: R Foundation for Statistical Computing; 2025 [cited 2025 Sept 26]. Available from: https://www.r-project.org/

26. Schwarzer G. meta: General Package for Meta-Analysis [Internet]. CRAN; 2025 [cited 2025 Sept 26]. Available from: https://cran.r-project.org/web/packages/meta/index.html

27. Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019 Oct 8;93(15):e1452–62.

28. Al-Mahdawi A, Hatem A, Hossam HM, et al. Efficacy and safety of natalizumab's extended interval dosing in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2023; [cited 2025 Sept 12]. Available from: https://www.sciencedirect.com/science/article/pii/S2211034823007022

29. Bernardes C, Fernandes C, Cunha C, Nunes C, Macário C, Sousa L, et al. Natalizumab extended interval dosing: what about wearing-off effect? J Neurol Sci. 2024 Mar 15;458:120–6.

30. Butzkueven H, Kappos L, et al. Similar clinical outcomes for natalizumab patients switching to every-6-week dosing versus remaining on every-4-week dosing in real-world practice. Presented at: ACTRIMS-ECTRIMS; 2020. Available from: https://a2-downloads.de/…

31. Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2019;16(2):448–56.

32. Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Natalizumab discontinuation in a Dutch real-world cohort. Mult Scler Relat Disord. 2021 Jul;52:102974.

33. De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, et al. MRI activity and extended interval natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci. 2021 May 15;424:117385.

34. Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Switching to 6-week dosing of natalizumab versus continuing 4-week dosing in RRMS (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608–19.

35. Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martínez F, Cabrera-Maqueda JM, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis: study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord. 2020 Sep

1;44:102274.

36. Gardinetti M, Barcella V, Frigeni B, Frigo M, Fusco ML, Rottoli M. Natalizumab withdrawal in multiple sclerosis RR patients: what to expect. Neurol Disord Ther. 2017;1(1):1–8.

37. González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, et al. Catastrophic outcome of patients with a rebound after natalizumab discontinuation. Brain Behav. 2017 Apr;7(4):e00671.

38. Haas J, Schneider K, Schwarz A, Korporal-Kuhnke M, Faller S, von Glehn F, et al. Th17 cells: a prognostic marker for MS rebound after natalizumab cessation? Mult Scler. 2016 Jan;23(1):114–8.

39. Jakimovski D, Kavak KS, Zakalik K, McGraw C, Gottesman M, Coyle PK, et al. Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State MS Consortium study. J Neurol Sci. 2023 Dec 15;455:122781.

40. Jeantin L, Boudot de la Motte M, Deschamps R, Gueguen A, Gout O, Lecler A, et al. Natalizumab extended-interval dosing in a real-life setting. J Neurol Sci. 2023 Jul 15;450:120689.

41. Kaufman M, Cree BAC, de Sèze J. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015 Feb;262(2):426–36.

42. Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, et al. Predictors of relapse and disability progression after discontinuing DMTs in MS. J Neurol Sci. 2018 Aug;391:72–6.

43. Mustonen T, Rauma I, Hartikainen P, Krüger J, Niiranen M, Selander T, et al. Risk factors for reactivation of clinical disease activity in MS after natalizumab cessation. Mult Scler Relat Disord. 2020 Feb;38:101493.

44. Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm. 2016 Nov;3(6):e297.

45. Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C, et al. Real-world effectiveness of natalizumab extended-interval dosing in a French cohort. Neurol Ther. 2023;12(2):529–42.

46. Riancho J, Setien S, Sánchez de la Torre JR, Torres-Barquin M, Misiego M, Pérez JL, et al. Does extended-interval dosing of natalizumab preserve effectiveness in multiple sclerosis? A 7-year retrospective observational study. Front Immunol. 2021 Mar 25;12:614715.

47. Ruggieri S, Ianniello A, Grimaldi LM, et al. Different regimen of natalizumab treatment in multiple sclerosis patients: a real-world study in Italy. Mult Scler Relat Disord. 2019;28:213–20.

48. Ryerson LZ. Extending natalizumab treatment up to eight weeks: updated multicenter analysis. 2015. Available from: https://www.researchgate.net/publication/282766495

49. Ruggieri S, Ianniello A, Copetti M, Altieri M, Buscarinu MC, Centonze D, et al. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience. Neurotherapeutics. 2024 Feb 26;21(3):e00338.

50. Toorop AA, Noteboom S, Steenwijk MD, Gravendeel JW, Jasperse B, Barkhof F, et al. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in MS. Mult Scler. 2024 Feb;30(2):266–71.

51. van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI, et al. Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology. 2020 Aug 11;95(6):e745–54.

52. Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, et al. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937–43.

53. Yamout B. Efficacy and safety of natalizumab extended-interval dosing. Mult Scler Relat Disord. 2018 Jan;24:113–6.